Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson 1Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson 1Q11

Worldwide Pharmaceutical sales were $6.1 billion in the quarter.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson 1Q11

1Q Revenues: $16.2 billion (+4%)

1Q Earnings: $3.5 billion (-23%)

Comments: Worldwide Pharmaceutical sales were $6.1 billion in the quarter (+8%), with domestic sales down 1% and international sales up 7%. Remicade sales were up 8% to $1.3 billion. Levaquin/Floxin sales were up 17% to $434 million. Concerta sales were up 10% to $362 million. Prezista sales were up 42% to $266 million. Procrit/Eprex sales were down 24% to $397 million. Topamax sales were down 13% to $129 million. Worldwide Consumer sales were $3.7 billion (-2%), with domestic sales down 14%, impacted by the suspension of manufacturing at the McNeil Consumer Healthcare facility in Fort Washington, PA. International sales increased 6%. Worldwide Medical Devices and Diagnostics sales were $6.4 billion (+3%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters